Molecular Therapeutics Theme 1 Accomplishments

Identify and validate novel therapeutics, targets and pathways for selective tumor targeting and where possible advancing these into clinical trials. Research focus includes:

Scientific Accomplishments

Drs. Matherly and Polin have developed potent novel tumor-targeted cytotoxic agents based on the folate platform with selective membrane transport by the proton-coupled folate transporter (PCFT) and folate receptor (FR) α over the ubiquitously expressed reduced folate carrier. PCFT and FRα are highly expressed in tumors and provide means of selective tumor targeting. Studies in clinically relevant tumor cell models confirmed antitumor effects and in vivo efficacies were demonstrated with FRα- and PCFT- expressing human ovarian and mesothelioma xenografts in SCID mice. Plans are to progress these novel agents to clinical trials.

  • Lead researcher: Dr. Matherly
  • Collaborative researcher: Dr. Polin

Drs. Mohammad and Philip identified rationally designed nuclear transport inhibitors for treating pancreatic cancer. Their focus is on chromosome maintenance protein 1 (CRM1), a ubiquitous transport receptor that controls the nuclear export of key tumor suppressor and growth regulatory proteins. Over-expression of CRM1 is frequent in pancreatic cancer and is associated with increased histological grade, tumor size, metastasis and decreased survival. Based on promising preclinical results in pancreatic cancer cell lines and non-transformed human pancreatic ductal epithelial cells, patients are being enrolled on a phase I/IIb investigator-initiated clinical trial with the lead compound of this series.

  • Lead Researchers: Drs. Mohammad and Philip
  • Collaborative researchers: Drs. Heath, Mahaseth, Mohammad, Philip, Shields, Vaishampayan, and Harper

Investigation of ELK1 as a regulator of androgen receptor growth signaling receptors in prostate cancer. Researchers found that ELK1 directs a selective and sustained induction of genes that are critical for growth signaling by androgen receptor in prostate cancer cells. Studies are exploring whether disrupting the ELK1-androgen receptor interaction is possible and whether drugs can be developed for this purpose. With Dr. Heath, Dr. Ratnam is extending these studies to patients with the goal of an investigator-initiated clinical trial targeting the ELK1-AR interaction in prostate cancer patients.

  • Lead Researcher: Dr. Ratnam
  • Collaborative Researcher: Dr. Heath

The Latest From Karmanos Cancer Institute

News

Beating back cancer

“To hear that was a godsend.” It was a familiar face that delivered the news to Lori. It was Nov. 29, and Lori was sitting in the McLaren Oakland ...

Read More

Johanna’s Legacy: Tribute gift supports better treatments for ovarian cancer

Give women the facts and they will take care of their health. That’s the premise behind the philanthropic drive of Sheryl Silver, a leading nation...

Read More

Time to Do a Skin Check

“Right now is a good time to take inventory of your skin.” There was plenty of sun in Michigan this summer. Spending more time outdoors and enjoyi...

Read More
News

ACS CAN Michigan Candid Connection, August 2021 — April Brown

Listen Now

Dr. Al Hallak on alcohol and cancer with WJR

Listen Now

ACS CAN MI CANdid Connection, July 2021 — Anthony Shields, M.D.

Listen Now